Novo Nordisk's facility in Monksland Athlone. Novo Nordisk expanding to facilitate production of weight loss drugPharmaceutical firm Novo Nordisk has announced that it will manufacture the weight loss drug Wegovy in tablet form at its Athlone facility. The company intends to expand its manufacturing facility in Athlone to facilitate production of the drug, Novo Nordisk CEO Mike Doustdar told Bloomberg media in an interview. Only last year Novo Nordisk announced 115 redundancies at its plant in Athlone. The Wegovy tablet was launched in the United States in January with approximately 240,000 people using the product to date.

Source: Irish Independent February 13, 2026 11:07 UTC